Schematic illustration of the experimental layout used to obtain data shown in (B)–(N). i.c., intracranial; IF, immunofluorescence. In brief, murine glioma cell lines CT-2A or CT-2A-Ova were implanted intracranially in C57BL/6 mice on day 0, followed by intravenous administration of either AAV-GFP or AAV-LIGHT on days 4, 7, and 10 post-tumor implantation. LTβR-IgG construct or control IgG were administered intraperitoneally every 7 days starting at day -4 from tumor implantation. Mice were sacrificed at the humane endpoint, and tumor-bearing brains were collected for immunofluorescence analysis (n = 20 mice/group), or mice were sacrificed on day 14 post-tumor implantation, and tumor-bearing brains were harvested for flow cytometry analysis of tumor-infiltrating T cells (n = 3–7 mice/group).
